Afatinib 30 mg
$1,250.00
| Quantity Value | Price | Price/Unit | Quantity | Add To Cart |
|---|---|---|---|---|
| – 28 Tablets | $1,250.00 | $0.15 / Piece |
|
SKU : N/A
Category : Cancer
Afatinib 30 mg is an oral cancer therapy containing Afatinib, used under medical supervision to treat EGFR-positive non-small cell lung cancer.
Product Overview
Afatinib 30 mg is a prescription medication used primarily in the treatment of certain types of non-small cell lung cancer (NSCLC). It belongs to a class of targeted cancer therapies known as tyrosine kinase inhibitors (TKIs) and is prescribed under medical supervision. This medicine is intended for patients whose cancer cells exhibit specific epidermal growth factor receptor (EGFR) mutations, helping to manage disease progression and improve patient outcomes. Afatinib is available in oral tablet form and should only be used following a healthcare provider’s recommendation.
How It Works
Afatinib functions by inhibiting the activity of proteins called epidermal growth factor receptors (EGFRs) on the surface of cancer cells. These receptors play a critical role in signaling pathways that promote cell growth and division. By blocking EGFR activity, Afatinib interferes with the uncontrolled proliferation of cancer cells, thereby slowing tumor growth. Its mechanism is targeted, meaning it specifically affects cancer cells with EGFR mutations, which can help reduce the impact on healthy cells compared to traditional chemotherapy.
Uses / Indications
Afatinib 30 mg is primarily indicated for the treatment of locally advanced or metastatic NSCLC in patients with confirmed EGFR mutations. It may be prescribed as a first-line therapy or in cases where other treatments have proven ineffective. While Afatinib can help manage cancer progression, it is not a cure, and its effectiveness is optimized when used as part of a comprehensive treatment plan under medical supervision.
Composition
-
Active Ingredient: Afatinib (30 mg per tablet)
-
Dosage Form: Film-coated oral tablets
Each tablet contains Afatinib as the sole active component. The tablets are formulated to provide consistent absorption and bioavailability when taken orally as directed by a healthcare provider.
Administration
Afatinib 30 mg is administered orally, typically once daily, and should be taken on an empty stomach or as instructed by a physician. Dosage adjustments may be required based on individual patient response, tolerance, and any side effects experienced. Regular monitoring by a healthcare professional is essential to ensure safe and effective therapy. Patients should follow all instructions regarding missed doses, interactions with other medications, and management of side effects.
Storage Instructions
Store Afatinib 30 mg tablets at room temperature, away from moisture and heat, in their original packaging. Keep out of reach of children and pets. Avoid storing the medication in bathrooms or other humid areas, as this can affect stability and efficacy.
Important Information / Warning
Afatinib 30 mg must only be used under the guidance of a qualified healthcare provider. Patients should disclose their full medical history, including liver or kidney conditions, heart issues, or other medications currently being taken, as these may influence treatment safety. Common side effects may include diarrhea, skin rash, and mouth sores, which should be promptly reported to a healthcare professional. Serious adverse reactions, though rare, may require immediate medical attention. Regular monitoring and adherence to medical instructions are crucial for safe therapy.
External Resource: For more information on Afatinib, its clinical use, and safety guidelines, visit the National Cancer Institute’s page on Afatinib.
| Pack Size |
28 Tablets |
|---|
